IntrinsicIntrinsic
← All summaries

Aldeyra Therapeutics, Inc.

ALDX
Financials & Chart →

Business Summary

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing innovative therapies for immune-mediated diseases by modulating protein systems rather than single protein targets. The company's core business model revolves around the preclinical and clinical development of product candidates, with the ultimate goal of obtaining regulatory approval and commercializing these products, either directly or through collaborations. To date, Aldeyra has primarily funded its operations through the sale of common stock, convertible preferred stock, convertible promissory notes, warrants, and borrowings under debt facilities, as it currently generates no revenue from product sales .

The company's product pipeline includes RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for systemic and retinal immune-mediated diseases. Late-stage product candidates are reproxalap, a RASP modulator for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa. The RASP modulator platform is designed to bind and deplete RASP, which are elevated in ocular and systemic inflammatory diseases, aiming for broad anti-inflammatory effects while minimizing toxicity. Reproxalap, administered topically, has been studied in approximately 2,700 patients and observed to be generally well tolerated with mild and transient instillation site irritation as the most common adverse event . ADX-2191, a novel intravitreal formulation of methotrexate, is being developed for primary vitreoretinal lymphoma and retinitis pigmentosa.

For the fiscal year ended December 31, 2025, Aldeyra reported a net loss of approximately $33.8 million , an improvement from the net loss of $55.9 million for the same period in 2024. Research and development expenses decreased significantly to $25.7 million in 2025 from $48.2 million in 2024, representing a decrease of approximately $22.5 million or 46.8% . General and administrative expenses also decreased to $9.6 million in 2025 from $11.9 million in 2024, a reduction of approximately $2.3 million or 19.3% . Total other income, net, was approximately $1.4 million in 2025, down from $4.3 million in 2024, primarily due to a $2.9 million decrease in interest income resulting from a decrease in investments.

The decrease in research and development expenses was primarily driven by a $10.5 million decrease in external clinical development costs, an $8.5 million decrease in drug product manufacturing costs, a $1.6 million decrease in external preclinical development costs, a $1.5 million decrease in personnel costs, and a $0.4 million decrease in consulting expenditures. Approximately 33% of the total research and development expenses in 2025 were related to late-stage product candidates, with reproxalap accounting for approximately 19% and ADX-2191 for 14% of this spend. The company's accumulated deficit as of December 31, 2025, stood at $484.0 million , with total stockholders' equity of $44.3 million . Cash and cash equivalents were $70.0 million at year-end 2025, compared to $54.5 million at year-end 2024. The company had $15.0 million outstanding under its Hercules Credit Facility as of December 31, 2025, with no amounts remaining available for borrowing .

During the reported period, Aldeyra made significant progress with its lead product candidate, reproxalap. The company resubmitted its New Drug Application (NDA) for reproxalap for dry eye disease in October 2024, including results from a chamber trial that achieved its primary endpoint (P=0.004) of reducing patient-reported ocular discomfort. However, the FDA issued a Complete Response Letter (CRL) on April 3, 2025, citing a lack of efficacy demonstration in treating ocular symptoms, primarily due to a baseline imbalance in symptom scores in the submitted trial . Following this, a second chamber trial achieved its primary endpoint (P=0.002) with no notable baseline imbalance, and the field trial was supportive of reproxalap's activity. The NDA was resubmitted for a second time on June 17, 2025, and accepted for review with a PDUFA date of December 16, 2025 . On December 15, 2025, the FDA requested the submission of the field trial, extending the PDUFA date to March 16, 2026 . For allergic conjunctivitis, reproxalap demonstrated consistent statistically significant activity in improving ocular itching and redness in Phase 2 and Phase 3 trials, including the INVIGORATE and INVIGORATE-2 trials.

In terms of strategic partnerships, Aldeyra entered into an exclusive option agreement with AbbVie Inc. on October 31, 2023, granting AbbVie an exclusive option to obtain a co-exclusive license for reproxalap in the United States and an exclusive license outside the United States. AbbVie paid a non-refundable $1.0 million option payment and a $5.0 million extension fee. If the collaboration agreement is entered into, AbbVie would pay a $100.0 million upfront cash payment (less the option and extension fees) and up to approximately $300.0 million in regulatory and commercial milestone payments, including a $100.0 million milestone for FDA approval. In the U.S., profits and losses would be split 60% for AbbVie and 40% for Aldeyra , with tiered royalties on net sales outside the U.S. As of February 27, 2026, AbbVie has not exercised the option . For ADX-2191, the company received a Special Protocol Assessment (SPA) Agreement Letter from the FDA in June 2025 for primary vitreoretinal lymphoma, with top-line results expected in 2026 . A Phase 2 clinical trial of ADX-2191 in retinitis pigmentosa showed statistical significance across multiple visual acuity and sensitivity endpoints .

Business Outlook

Aldeyra Therapeutics anticipates incurring additional research and development expenses for the foreseeable future as it advances ADX-248, ADX-246, and other compounds through preclinical and clinical development. The company expects its expenses to increase substantially as it prepares for commercializing reproxalap, if approved, either alone or with partners, and continues the development of ADX-2191, ADX-248, ADX-246, and other product candidates. These increases will also stem from expanded infrastructure, increased headcount, and higher legal, compliance, accounting, and investor relations expenses associated with being a public company .

A major growth area for Aldeyra is the potential commercialization of reproxalap for dry eye disease and allergic conjunctivitis. The company plans to discuss remaining regulatory requirements with the FDA for reproxalap for allergic conjunctivitis in light of positive results from the INVIGORATE and INVIGORATE-2 trials . The potential collaboration with AbbVie represents a significant opportunity, with a possible $100.0 million upfront payment (less prior option fees) and up to approximately $300.0 million in regulatory and commercial milestone payments, including a $100.0 million milestone for FDA approval of reproxalap. In the United States, a 60% / 40% profit and loss split with AbbVie is outlined, with tiered royalties on net sales outside the United States . Aldeyra will also conduct certain launch activities for reproxalap, with costs not exceeding mid-single-digit millions of dollars without AbbVie's approval, and 60% of these allowable expenses would be reimbursed by AbbVie upon option exercise.

Another key growth area is the development of ADX-2191 for primary vitreoretinal lymphoma and retinitis pigmentosa. Top-line results from the clinical trial for primary vitreoretinal lymphoma are expected in 2026 . For retinitis pigmentosa, Aldeyra plans to initiate a Phase 2/3 clinical trial in the first half of 2026 . This randomized, double-masked, multicenter trial will compare peripheral vision sensitivity to green light across high and low doses of ADX-2191 and sham injections in approximately 45 retinitis pigmentosa patients (15 patients per arm) over 12 months of therapy .

The company also plans to initiate clinical trials of next-generation RASP modulators ADX-248 (oral administration) and ADX-246 (intravitreal injection) in atopic dermatitis and dry age-related macular degeneration (AMD) in 2026 and 2027, respectively . ADX-248 and ADX-246 are described as more potent RASP modulators than ADX-629, with ADX-248 optimized for once-daily oral administration . A Phase 1 clinical trial of ADX-248 is currently ongoing .

Operationally, Aldeyra expects general and administrative expenses to increase in the future as it expands operating activities and incurs additional costs associated with being a publicly-traded company, including higher consulting costs, commercialization fees, legal fees, accounting fees, insurance premiums, and investor relations fees . The company does not own or operate manufacturing facilities and will continue to depend on third-party contract manufacturers for raw materials, drug substance, and finished drug product for preclinical research and clinical trials, and intends to enter into agreements for commercial production if product candidates are approved .

For capital allocation, Aldeyra's research and development expenses totaled $25.7 million for the year ended December 31, 2025. The company had cash and cash equivalents of $70.0 million as of December 31, 2025, and believes these resources will be sufficient to fund projected operating expenses and debt obligations for at least twelve months from February 27, 2026 . Aldeyra has an Open Market Sales Agreement with Jefferies to sell up to $75.0 million in common stock, with no sales made as of December 31, 2025 . The Hercules Credit Facility has $15.0 million outstanding as of December 31, 2025, with interest-only payments until April 1, 2026, and a maturity date of April 1, 2026 .

Risk Factors

Aldeyra faces significant risks, including the critical dependence on successful commercialization of reproxalap, which has received two Complete Response Letters from the FDA, indicating a lack of demonstrated efficacy in treating ocular symptoms and requiring at least one additional adequate and well-controlled study . The FDA's recent policy shift towards "radical transparency" in releasing Complete Response Letters could lead to negative publicity, loss of investor confidence, damage to collaborations, increased litigation risk, and heightened SEC scrutiny . If AbbVie does not exercise its exclusive option for reproxalap, Aldeyra would be solely responsible for funding further development and commercialization, potentially requiring substantial additional capital that may not be available on acceptable terms . The company has incurred significant operating losses, with a net loss of $33.8 million in 2025 and an accumulated deficit of $484.0 million , and expects to incur further losses, requiring substantial additional financing in the near future . Delays or failures in clinical trials, which are conducted by third parties, could increase costs and delay revenue generation . The company's reliance on a limited number of Contract Manufacturing Organizations (CMOs) and the complexity of drug manufacturing pose risks of supply disruptions, increased costs, and delays in regulatory approvals . An FDA cGMP inspection of a third-party manufacturer of reproxalap in August 2025 identified deficiencies, though the inspection was subsequently closed with a Voluntary Action Indicated (VAI) classification . Competition from established therapies and new treatments, many from companies with substantially greater resources, could reduce or eliminate Aldeyra's commercial opportunity . Changes in U.S. patent law could diminish the value of patents, impairing the ability to protect product candidates . The company is also subject to various legal and regulatory risks, including anti-kickback, fraud and abuse laws, and potential product liability lawsuits, which could result in significant penalties or liabilities .

Management Priorities

Management emphasizes its devotion to discovering innovative therapies for immune-mediated diseases through a unique approach of modulating protein systems to optimize multiple pathways while minimizing toxicity. A key strategic priority is the successful development and potential commercialization of reproxalap, despite facing regulatory hurdles as evidenced by two Complete Response Letters from the FDA regarding its NDA for dry eye disease. Management has actively engaged with the FDA, amending trial designs and resubmitting the NDA, with a current PDUFA target action date of March 16, 2026 . Another strategic focus is the potential collaboration with AbbVie for reproxalap, which could provide a $100.0 million upfront payment and up to approximately $300.0 million in milestone payments, and a 60% / 40% profit and loss split in the U.S. . The company also highlights the continued development of ADX-2191 for primary vitreoretinal lymphoma and retinitis pigmentosa, with top-line results for the former expected in 2026 and a Phase 2/3 trial for the latter planned for the first half of 2026 . Management acknowledges the need for substantial additional funding to support ongoing and planned activities, including clinical trials and potential commercialization efforts, and will seek financing through equity, debt, or partnerships.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — The RASP Modulator Platform
  3. [3] Item 7, MD&A — Net Loss
  4. [4] Item 7, MD&A — Net Loss
  5. [5] Item 7, MD&A — Research and Development Expenses
  6. [6] Item 7, MD&A — Research and Development Expenses
  7. [7] Item 7, MD&A — Research and Development Expenses
  8. [8] Item 7, MD&A — Research and Development Expenses
  9. [9] Item 7, MD&A — General and Administrative Expenses
  10. [10] Item 7, MD&A — General and Administrative Expenses
  11. [11] Item 7, MD&A — General and Administrative Expenses
  12. [12] Item 7, MD&A — General and Administrative Expenses
  13. [13] Item 7, MD&A — Other Income (Expense)
  14. [14] Item 7, MD&A — Other Income (Expense)
  15. [15] Item 7, MD&A — Other Income (Expense)
  16. [16] Item 7, MD&A — Research and Development Expenses
  17. [17] Item 7, MD&A — Research and Development Expenses
  18. [18] Item 7, MD&A — Research and Development Expenses
  19. [19] Item 7, MD&A — Research and Development Expenses
  20. [20] Item 7, MD&A — Research and Development Expenses
  21. [21] Item 7, MD&A — Research and Development Expenses
  22. [22] Item 7, MD&A — Research and Development Expenses
  23. [23] Item 7, MD&A — Research and Development Expenses
  24. [24] Item 7, MD&A — Net Loss
  25. [25] Item 7, MD&A — Liquidity and Capital Resources
  26. [26] Item 7, MD&A — Liquidity and Capital Resources
  27. [27] Item 7, MD&A — Liquidity and Capital Resources
  28. [28] Item 7, MD&A — Liquidity and Capital Resources
  29. [29] Item 7, MD&A — Liquidity and Capital Resources
  30. [30] Item 1, Business — Dry Eye Disease
  31. [31] Item 1, Business — Dry Eye Disease
  32. [32] Item 1, Business — Dry Eye Disease
  33. [33] Item 1, Business — Dry Eye Disease
  34. [34] Item 1, Business — Dry Eye Disease
  35. [35] Item 1, Business — AbbVie Option Agreement
  36. [36] Item 1, Business — AbbVie Option Agreement
  37. [37] Item 1, Business — AbbVie Option Agreement
  38. [38] Item 1, Business — AbbVie Option Agreement
  39. [39] Item 1, Business — AbbVie Option Agreement
  40. [40] Item 1, Business — AbbVie Option Agreement
  41. [41] Item 1, Business — AbbVie Option Agreement
  42. [42] Item 1, Business — Primary Vitreoretinal Lymphoma
  43. [43] Item 1, Business — Retinitis Pigmentosa
  44. [44] Item 7, MD&A — General and Administrative Expenses
  45. [45] Item 1, Business — Allergic Conjunctivitis
  46. [46] Item 1, Business — AbbVie Option Agreement
  47. [47] Item 1, Business — AbbVie Option Agreement
  48. [48] Item 1, Business — AbbVie Option Agreement
  49. [49] Item 1, Business — AbbVie Option Agreement
  50. [50] Item 1, Business — AbbVie Option Agreement
  51. [51] Item 1, Business — AbbVie Option Agreement
  52. [52] Item 1, Business — Primary Vitreoretinal Lymphoma
  53. [53] Item 1, Business — Retinitis Pigmentosa
  54. [54] Item 1, Business — Retinitis Pigmentosa
  55. [55] Item 1, Business — Retinitis Pigmentosa
  56. [56] Item 1, Business — Systemic RASP Modulation for the Treatment of Immune-Mediated Diseases
  57. [57] Item 1, Business — Systemic RASP Modulation for the Treatment of Immune-Mediated Diseases
  58. [58] Item 1, Business — Systemic RASP Modulation for the Treatment of Immune-Mediated Diseases
  59. [59] Item 7, MD&A — General and Administrative Expenses
  60. [60] Item 1, Business — Manufacturing
  61. [61] Item 7, MD&A — Research and Development Expenses
  62. [62] Item 7, MD&A — Liquidity and Capital Resources
  63. [63] Item 7, MD&A — Liquidity and Capital Resources
  64. [64] Item 7, MD&A — Liquidity and Capital Resources
  65. [65] Item 7, MD&A — Liquidity and Capital Resources
  66. [66] Item 7, MD&A — Liquidity and Capital Resources
  67. [67] Item 7, MD&A — Liquidity and Capital Resources
  68. [68] Item 1A, Risk Factors — Risks Related to the Potential Development and Commercialization of Reproxalap and our Product Candidates
  69. [69] Item 1A, Risk Factors — The FDA's shift toward "radical transparency," including plans to release future complete response letters promptly after they are issued to sponsors, could have an adverse impact on our business and adversely affect our commercial prospects.
  70. [70] Item 1A, Risk Factors — If the AbbVie Option is not exercised by AbbVie and we remain responsible for funding further development and commercialization of reproxalap, we may be unable to raise the additional capital required to further develop and commercialize reproxalap or enter into a collaboration agreement with another pharmaceutical company with equivalent or comparable terms, or at all.
  71. [71] Item 1A, Risk Factors — We have incurred significant operating losses since inception, and we expect to incur significant losses over the next several years. We may never become profitable or, if achieved, be able to sustain profitability.
  72. [72] Item 1A, Risk Factors — We have incurred significant operating losses since inception, and we expect to incur significant losses over the next several years. We may never become profitable or, if achieved, be able to sustain profitability.
  73. [73] Item 1A, Risk Factors — We will require substantial additional financing, and a failure to obtain the necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.
  74. [74] Item 1A, Risk Factors — We rely on third parties to conduct our clinical trials. If any third-party does not meet our deadlines or otherwise conduct the trials as required and in accordance with regulations, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates when expected, or at all.
  75. [75] Item 1A, Risk Factors — Our reliance on a limited number of Contract Manufacturing Organizations (CMOs), as well as the complexity of drug manufacturing and the difficulty of scaling a manufacturing process, could cause the delay of clinical trials, regulatory submissions, required approvals, or commercialization of our product candidates, and cause us to incur higher costs and prevent us from commercializing our product candidates successfully.
  76. [76] Item 1A, Risk Factors — We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our products.
  77. [77] Item 1A, Risk Factors — If our competitors develop treatments for the target indications of our product candidates that are approved more quickly than ours, marketed more successfully, or demonstrated to be safer or more effective than our product candidates, our commercial opportunity will be reduced or eliminated.
  78. [78] Item 1A, Risk Factors — Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  79. [79] Item 1A, Risk Factors — If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of reproxalap or our other product candidates.
  80. [80] Item 1, Business — Dry Eye Disease
  81. [81] Item 1, Business — AbbVie Option Agreement
  82. [82] Item 1, Business — AbbVie Option Agreement
  83. [83] Item 1, Business — AbbVie Option Agreement
  84. [84] Item 1, Business — Primary Vitreoretinal Lymphoma
  85. [85] Item 1, Business — Retinitis Pigmentosa

Analysis on 5/19/2026